InvestorsHub Logo
Post# of 251654
Next 10
Followers 827
Posts 119518
Boards Moderated 15
Alias Born 09/05/2002

Re: Titan V post# 206654

Monday, 12/05/2016 7:18:55 PM

Monday, December 05, 2016 7:18:55 PM

Post# of 251654
Reuters' saying that Gazyva/Treanda vs Rituxan/Treanda raised 3-year survival from 92% to "only" 94% makes the benefit sound trifling, but it's actually a 25% reduction in the risk of death during the first three years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.